The pills, dubbed Januvia and Galvus, are expected to reach the U.S. market in less than a year and could bring in combined sales of $5 billion by 2010, according to industry analysts.

Yesterday Merck & Co., besides releasing first quarter results, announced preliminary results from the Tecos trial. Tecos was designed to gauge the cardiovascular impact of Januvia, a drug which ...

Merck Receives Positive CHMP Opinion for JANUVIA® (sitagliptin) and JANUMET ... and is currently under review. The use of JANUVIA and JANUMET in combination with insulin is investigational in ...

Positive Opinion For Type 2 Diabetes Treatment, JANUVIA - First In New Class Of Oral Treatments Known As DPP-4 Inhibitors, European Union JANUVIA (sitagliptin), Merck, Sharp & Dohme's treatment ...

Diabetes drugs including Merck & Co.’s Januvia, Bristol-Myers Squibb Co.’s Byetta and Novo Nordisk A/S’s Victoza are being scrutinized by U.S. regulators for a possible link to pre-cancerous ...

The US Food and Drug Administration has agreed to review Merck & Co’s application to market its experimental diabetes drug, Januvia (sitagliptin phosphate), placing the firm ahead of the pack in the ...

Merck Welcomes Independent Review of the Safety Profile of JANUVIA ® (sitagliptin) and Other Diabetes Medicines WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck, known as MSD outside the United ...

Pressure is building to take a deeper dive into the cancer risks of incretin mimetics, a class of drugs for Type 2 diabetes that includes blockbusters like Merck's Januvia and Novo Nordisk's Victoza.

Medicare typically covers prescription drugs, such as Januvia, from Part D plans. Januvia costs with Medicare The cost of Januvia (sitagliptin) varies by dosage, a person’s plan type, and their ...

Testing found nitrosamine contamination in some samples of Januvia, but regulators will allow Merck to continue selling the drug for now. By Andrew Jacobs The Food and Drug Administration said ...